Clinical Trial Update: A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB [NA]

View source ↗

Summary

A 90-day, Phase 3 open-label exploratory trial of RELiZORB is currently recruiting for Short Bowel Syndrome and malabsorption.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malabsorption
• Short Bowel Syndrome

Drugs mentioned

• RELiZORB

Snippet

Sponsor: Boston Children's Hospital | Conditions: Short Bowel Syndrome, Malabsorption | NA | Status: RECRUITING